Last Updated : April 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| TBC | risperidone | Schizophrenia, adults | Suspended | |||
| TBC | ruxolitinib | atopic dermatitis | Suspended | |||
| TBC | pegcetacoplan | Geographic atrophy secondary to age-related macular degeneration | Pending | |||
| TBC | cabotegravir | HIV-1 infection, pre-exposure prophylaxis | Active | |||
| TBC | lebrikizumab | atopic dermatitis | Active | |||
| TBC | zilucoplan | Generalized myasthenia gravis (gMG) | Active | |||
| TBC | clindamycin plus benzoyl peroxide and adapalene | acne vulgaris | Active | |||
| TBC | ivosidenib | Acute myeloid leukemia (AML) | Active | |||
| TBC | sotatercept | Pulmonary arterial hypertension (WHO group 1) | Received | |||
| TBC | eplontersen | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Received |
Last Updated : April 19, 2024